Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 10.9x - 12.0x | 11.5x |
| Selected Fwd P/E Multiple | 8.3x - 9.2x | 8.8x |
| Fair Value | €27.62 - €30.53 | €29.07 |
| Upside | 46.5% - 61.9% | 54.2% |
| Benchmarks | - | Full Ticker |
| Assertio Holdings, Inc. | - | NasdaqCM:ASRT |
| Xeris Biopharma Holdings, Inc. | - | NasdaqGS:XERS |
| Supernus Pharmaceuticals, Inc. | - | NasdaqGM:SUPN |
| Prestige Consumer Healthcare Inc. | - | NYSE:PBH |
| Corcept Therapeutics Incorporated | - | NasdaqCM:CORT |
| Amphastar Pharmaceuticals, Inc. | - | DB:29A |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| ASRT | XERS | SUPN | PBH | CORT | 29A | |||
| NasdaqCM:ASRT | NasdaqGS:XERS | NasdaqGM:SUPN | NYSE:PBH | NasdaqCM:CORT | DB:29A | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | -8.2% | 8.6% | 8.2% | 26.7% | ||
| 3Y CAGR | NM- | NM- | 11.4% | 1.5% | 7.5% | 36.9% | ||
| Latest Twelve Months | 90.8% | 46.3% | 1131.1% | 3.8% | 5.6% | -19.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -55.2% | -157.6% | 10.3% | 13.2% | 25.3% | 15.5% | ||
| Prior Fiscal Year | -218.3% | -38.0% | 0.2% | 18.6% | 21.9% | 21.3% | ||
| Latest Fiscal Year | -17.3% | -27.0% | 11.2% | 18.9% | 20.7% | 21.8% | ||
| Latest Twelve Months | -25.7% | -13.0% | 9.7% | 19.0% | 18.4% | 18.6% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -37.5x | 155.4x | 13.8x | 10.9x | 69.3x | 6.5x | ||
| Price / LTM Sales | 0.6x | 4.5x | 3.5x | 2.9x | 10.6x | 1.5x | ||
| LTM P/E Ratio | -2.3x | -34.5x | 35.8x | 15.2x | 57.7x | 8.2x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -34.5x | 15.2x | 57.7x | |||||
| Historical LTM P/E Ratio | 11.3x | 21.9x | 143.7x | |||||
| Selected P/E Multiple | 10.9x | 11.5x | 12.0x | |||||
| (x) LTM Net Income | 135 | 135 | 135 | |||||
| (=) Equity Value | 1,466 | 1,543 | 1,620 | |||||
| (/) Shares Outstanding | 46.5 | 46.5 | 46.5 | |||||
| Implied Value Range | 31.52 | 33.18 | 34.84 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 27.06 | 28.49 | 29.91 | 18.85 | ||||
| Upside / (Downside) | 43.6% | 51.1% | 58.7% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ASRT | XERS | SUPN | PBH | CORT | 29A | |
| Value of Common Equity | 70 | 1,105 | 2,312 | 3,227 | 7,618 | 1,021 | |
| (/) Shares Outstanding | 95.8 | 161.5 | 56.1 | 49.2 | 105.4 | 46.5 | |
| Implied Stock Price | 0.73 | 6.84 | 41.23 | 65.58 | 72.30 | 21.95 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |
| Implied Stock Price (Trading Cur) | 0.73 | 6.84 | 41.23 | 65.58 | 72.30 | 18.85 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |